Vanguard Group
RANI icon

Vanguard Group’s Rani Therapeutics RANI Stock Holding History

Vanguard Group’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.9M Buy
5,109,368
+4,224,759
+478% +$6.37M ﹤0.01% 3134
2025
Q3 		$442K Buy
884,609
+84,930
+11% +$44.3K ﹤0.01% 3980
2025
Q2 		$411K Hold
799,679
– – ﹤0.01% 3964
2025
Q1 		$1.01M Buy
799,679
+89,851
+13% +$133K ﹤0.01% 3707
2024
Q4 		$972K Hold
709,828
– – ﹤0.01% 3777
2024
Q3 		$1.53M Hold
709,828
– – ﹤0.01% 3639
2024
Q2 		$2.7M Buy
709,828
+24,525
+4% +$127K ﹤0.01% 3470
2024
Q1 		$2.13M Buy
685,303
+16,956
+3% +$58.3K ﹤0.01% 3572
2023
Q4 		$2.22M Sell
668,347
-742
-0.1% -$1.72K ﹤0.01% 3562
2023
Q3 		$1.46M Hold
669,089
– – ﹤0.01% 3698
2023
Q2 		$2.76M Hold
669,089
– – ﹤0.01% 3560
2023
Q1 		$3.45M Hold
669,089
– – ﹤0.01% 3475
2022
Q4 		$3.95M Buy
669,089
+18,111
+3% +$132K ﹤0.01% 3416
2022
Q3 		$6.24M Buy
650,978
+317,849
+95% +$3.37M ﹤0.01% 3208
2022
Q2 		$3.44M Buy
333,129
+43,022
+15% +$494K ﹤0.01% 3558
2022
Q1 		$3.92M Buy
290,107
+4,561
+2% +$75.7K ﹤0.01% 3644
2021
Q4 		$4.67M Buy
285,546
+2,333
+0.8% +$53K ﹤0.01% 3653
2021
Q3 		$5.05M Buy
+283,213
New +$4.9M ﹤0.01% 3658

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group's RANI Position: Q4 2025 in Review

Vanguard Group increased its Rani Therapeutics (RANI) stake by 478% in Q4 2025, buying an estimated $6.37M and bringing the position to 5,109,368 shares worth $6.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3134.

Vanguard Group first reported a position in RANI in Q3 2021 and has held it in 18 quarters since. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • Vanguard Group held 5,109,368 shares of Rani Therapeutics worth $6.9M as of Q4 2025.
  • Vanguard Group bought 4,224,759 Rani Therapeutics shares in Q4 2025, an estimated $6.37M.
  • Rani Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3134 holding.
  • Vanguard Group first reported a position in Rani Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.